SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires latest quarterly results are driving discussion, with weaker operating performance in insurance, particularly GEICO, contrasted with a sharp increase in share repurchases. Traders are split between viewing the buybacks and large cash reserve as signs of management confidence and questioning whether the earnings softness and limited capital deployment will weigh on the shares.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

XLF is drawing attention after a sharp financial-sector pullback and put-heavy options activity, prompting debate over whether traders are hedging or positioning for further weakness. Bearish concerns include credit exposure and rate pressures, while others view the decline as profit-taking within a still-resilient sector trend.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Traders are debating whether Accenture can turn AI consulting projects into funded client deployments, with concerns that budget scrutiny and automation could squeeze billable hours and margins. Bearish commentary also points to resistance near $260 and an elevated RSI, while some investors remain positive on the companys recent run and insider buying.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the Florida Power and Light Company (FPL) and NextEra Energy Resources and NEET (NEER). The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEras planned Dominion acquisition and its push to expand power capacity for AI data centers are fueling debate. Bulls see greater scale and exposure to rising electricity demand, while skeptics point to financing and dilution risks, regulatory hurdles, and uncertainty over whether projected data-center loads will materialize.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines initial RASONQUE launch and quarterly results are driving attention, with traders highlighting stronger-than-expected early demand while debating whether high spending and the durability of the sales ramp justify the valuation. The discussion also points to a pending European decision and first-line pancreatic-cancer trials as potential next milestones.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Attention centers on lorundrostats upcoming FDA decision and additional clinical data, with traders debating the drugs prospects amid a steep share-price slide. Bulls point to prior positive trial results and the regulatory catalyst, while skeptics question commercialization against AstraZenecas competing Baxfendy and cite its slow launch and limited coverage.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention for its persistent selloff and perceived underperformance, with traders debating whether broader crypto weakness and continued selling will push it lower or create a buying opportunity. Bulls point to Stellars institutional tokenization and payments developments, including DTCC-related plans, while skeptics argue that adoption has yet to translate into stronger token performance.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a technology-sector correction and concerns that concentrated AI and data-center spending may not generate adequate returns. Traders point to mostly put-heavy options activity, debating whether it reflects hedging or bearish bets, while some see the pullback as an opportunity to buy.

NRG Energy, Inc. engages in the production, sale, and distribution of energy and energy services. It operates through the following segments: Texas, East, West/Services/Other, Vivint Smart Home, and Corporate Activities. The Texas segment includes all activities related to customer, plant and market operations in Texas, other than Cottonwood. The East segment engages in all activities related to customer, plant and market operations in the East. The West/Services/Other segment is focused on all activities related to customer, plant and market operations in the West and Canada, and activities related to the Cottonwood facility and other investments. The Vivint Smart Home segment is a smart home platform that provides customers with technology, products and services to create a smarter, greener, safer home. The company was founded in 1989 and is headquartered in Houston, TX.

NRG Energy Inc.

NRGs sharp rebound after a steep, volatile decline is drawing attention, with traders debating whether dip-buying signals a recovery or merely a temporary bounce. The discussion also weighs the AI and data-center power-demand thesis against concerns about softer electricity demand, earnings pressure, and whether expected growth is already priced in.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,078,194,480.417637 in circulation. The last known price of Algorand is 0.09693394 USD and is up 3.39 over the last 24 hours. It is currently trading on 586 active market(s) with $57,858,585.39 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention amid weak, volatile price action around the 910-cent area, with traders debating whether it can hold support and break resistance or continue lower. Bulls point to a possible altcoin rebound and Algorands quantum-resistant and tokenization features, while bears cite its prolonged underperformance and see further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anticipation around Omeros Q3 results is centered on whether rising U.S. YARTEMLEA sales will show continued launch growth. Many traders expect a strong report, while others question whether demand will meet optimistic expectations and see the results as a test of the drugs commercial momentum after the European regulatory setback.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPR NewswireNEW YORK, Nov. 5, 2026 NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPR NewswireNEW YORK, Oct. 22, 2026 NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz...

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

Equity

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. 


Futures Rise As Warsh Stays Mum, Tesla "Flying Car" Interrupts AI Liquidation

Futures Rise As Warsh Stays Mum, Tesla "Flying Car" Interrupts AI Liquidation

 US futures are higher, and small caps are leading, as the crowded-trade unwind that hammered chips, momentum and AI baskets all week takes a breather: Fed Chair Kevin Warsh said nothing about rates at the IMF...

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

European regulators rejected Omeros’ application for Narsoplimab, which is used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy.


Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros shares are trading lower Friday after the company announced that the EMA's CHMP upheld its negative opinion on narsoplimab for TA-TMA.read more...

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the companys marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell...

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.

This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded MetLife, Brinker, Plexus, West Pharma and Omeros, raising ratings and price targets.read more...

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Bearish Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright views the weakness following the morning’s negative Committee for Medicinal Products for Human Use opinion as overdone and sees a buying opportunity ahead of the next quarterly update.</li><li>Today’s decision, H.C. Wainwright said, does not change its forecasts, valuation, or investment thesis, while reiterating a Buy rating with a $33 price target.</li><li>The company now plans to license commercialization rights to a third party in the European Union (EU) if EU marketing authorization is granted.</li></ul><p>Shares of Omeros Corp (OMER) slumped 15% on Friday after a European Medicines Agency committee upheld a negative opinion on its drug for a serious post-transplant condition, though H.C. Wainwright dismissed the selloff as overdone.</p><p>The stock is now on track for its steepest one-day decline since late June.</p><h2 class="st-heading-2">What Did The Analyst Say?</h2><p>H.C. Wainwright views the weakness following the morning’s negative Committee for Medicinal Products for Human Use opinion as overdone and sees a buying opportunity ahead of the next quarterly update. The firm said it had already removed Europe entirely from its model when it lowered its price target to $33 in June after the committee's initial negative opinion.</p><p>Today’s decision, H.C. Wainwright said, does not change its forecasts, valuation, or investment thesis, while reiterating a Buy rating with a $33 price target. The price target still implies a potential upside of about 100% from the stock’s current trading levels around $16.</p><h2 class="st-heading-2">Second European Rejection For Yartemlea</h2><p>The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. This followed a re-examination of the committee’s original negative decision from June.</p><p>An eight-member ad hoc expert group recommended that outside experts examine individual patient data to better understand factors linked to treatment response and survival, the company said. Omeros said it had submitted substantial patient-level data in August, but the CHMP did not share those records with the expert panel.</p><h2 class="st-heading-2">US Approval Stands In Contrast</h2><p>Narsoplimab targets a rare and potentially fatal complication called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), which damages small blood vessels after stem cell transplants. The U.S. Food and Drug Administration approved it in December 2025 as the first and only treatment for the condition in patients aged two and older. No approved therapy exists for TA-TMA in Europe.</p><p>“We are deeply disappointed in the re-examination process and outcome,” said Omeros CEO Gregory A. Demopulos.</p><p>The company also said that it will terminate the compassionate use program for the drug in the EU and focus on its U.S. market. Current patients will receive enough supply to finish treatment, Omeros added.</p><p>The company now plans to license commercialization rights to a third party in the European Union (EU) if EU marketing authorization is granted.</p><h2 class="st-heading-2">How Did OMER Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$OMER" data-symbol-id="OMER" href="https://stocktwits.com/symbol/OMER" target="_blank">OMER stock</a> stayed within the bearish territory over the past 24 hours, while message volume rose from normal to high levels.</p><p>A Stocktwits user noted that the company has a partnership in place with Danish drugmaker Novo Nordisk for another drug called zaltenibart, which will eventually bring in milestone payments.</p><p><stembedurl>https://stocktwits.com/resq1/message/666714149</stembedurl></p><p>Another user said they weren't expecting “this big of a downward move.”</p><p><stembedurl>https://stocktwits.com/Chronite/message/666685540</stembedurl></p><p>OMER stock has fallen 6% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/xom-stock-climbs-on-4-5-b-refining-lift-estimate-goldman-sees-q3-eps-exceeding-wall-street-expectations/cZxKaeZRBsU">XOM Stock Climbs On $4.5B Refining Lift Estimate; Goldman Sees Q3 EPS Exceeding Wall Street Expectations</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. 

iShares Russell 2000 ETF

Omeros Corp

Vanguard Total Stock Market ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$16.92
Prev Close	$17.07
Open	$17.26
Dividend Yield	0.00%
50-Day Moving Average	$18.38
Beta	1.37
Avg. Volume	1.16M
PE Ratio	11.77

52-Week High	$21.24
52-Week Low	$6.24
Market Capitalization	$1.22B
EPS (Annual)	-$0.0528
Price to Book	-23.75
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OMER Fundamentals